Drug Trial Radar · NCT06488924
An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Nov 5, 2024
Primary completion
Apr 30, 2030
Study completion Apr 30, 2030
Sponsor
- Lead sponsor
- JCR Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I/ II, open-label study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIB patients.
Conditions
- Mucopolysaccharidosis III-B
Interventions
JR-446Drug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- To establish the safety and tolerability of JR-446 in MPSIIIB patientsTime frame: up to 4 years (multiple visits)
- To determine the pharmacodynamic effects of JR-446 in MPSIIIB patientsTime frame: up to 4 years (multiple visits)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Hiroshima University Hospital
Hiroshima, Japan
University of the Ryukyus Hospital
Okinawa, Japan
National Center for Child Health and Development
Tokyo, Japan
Mie University Hospital
Tsu, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.